Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.

In this study, we analyzed the antilipolytic effects of six N(6)-cyclopentyladenosine analogs in rats and developed a mechanistic pharmacokinetic-pharmacodynamic model to quantify and predict the tissue-selective action of adenosine A(1) receptor agonists in vivo. Freely moving rats received an i.v. infusion of vehicle or compound over 15 min. Arterial blood samples were taken at regular time intervals for the determination of concentrations of drugs using HPLC analysis and of nonesterified fatty acids (NEFAs). All N(6)-cyclopentyladenosine analogs that were investigated produced a significant decrease in the NEFA plasma concentration after i.v. infusion. The pharmacokinetic behavior of each ligand was described by a standard two-compartment model. The pharmacokinetic parameter estimates then were used to simultaneously fit the individual (n = 6-8) time-NEFA concentration profiles for each agonist to a physiological indirect response model in combination with the Hill equation to obtain estimates of the NEFA elimination rate constant (k(e)) and upper asymptote (fractional inhibition), midpoint location, and midpoint slope parameter (alpha, pEC(50), and n(H), respectively) of the concentration-effect relationship. Subsequently, the data were analyzed with the operational model of agonism to obtain estimates of in vivo affinity and efficacy. It was estimated that the in vivo density and/or coupling of adenosine A(1) receptors mediating antilipolytic effects is approximately 38 times higher compared with the receptors mediating bradycardia. The model predicts that it is possible to design ligands that produce significant inhibition of lipolysis and are completely devoid of cardiovascular effects in vivo.

[1]  J. Giraldo,et al.  Use of the operational model of agonism and [3H]prazosin binding to assess altered responsiveness of α1-adrenoceptors in the vas deferens of spontaneously hypertensive rat , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  M. Danhof,et al.  8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  A. Green,et al.  Characterization of human adipocyte adenosine receptors. , 1989, Biochemical and biophysical research communications.

[4]  A F Cohen,et al.  Estimating impossible curves using NONMEM. , 2003, British journal of clinical pharmacology.

[5]  J. Chambers,et al.  Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. , 1996, The Journal of pharmacology and experimental therapeutics.

[6]  M. Danhof,et al.  Selectivity of action of 8‐alkylamino analogues of N6‐cyclopentyladenosine in vivo: haemodynamic versus anti‐lipolytic responses in rats , 1998, British journal of pharmacology.

[7]  R. Donnelly,et al.  MECHANISMS OF INSULIN RESISTANCE AND NEW PHARMACOLOGICAL APPROACHES TO METABOLISM AND DIABETIC COMPLICATIONS , 1998, Clinical and experimental pharmacology & physiology.

[8]  T. Totsuka,et al.  Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. , 1998, Diabetes research and clinical practice.

[9]  A. IJzerman,et al.  Partial agonists for adenosine receptors , 1996 .

[10]  J. Black,et al.  A personal view of pharmacology. , 1996, Annual review of pharmacology and toxicology.

[11]  M. Danhof,et al.  Pharmacokinetic‐pharmacodynamic modelling of the anti‐lipolytic and anti‐ketotic effects of the adenosine A1‐receptor agonist N6‐(p‐sulphophenyl)adenosine in rats , 1997, British journal of pharmacology.

[12]  K. Clark,et al.  Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. , 1997, Journal of cardiovascular pharmacology.

[13]  T. Heffner,et al.  Ribose-modified adenosine analogues as adenosine receptor agonists. , 1986, Journal of medicinal chemistry.

[14]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[15]  M. Danhof,et al.  On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation. , 1997, Journal of pharmacological and toxicological methods.

[16]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[17]  M. Danhof,et al.  Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. , 1995, Journal of medicinal chemistry.

[18]  J. Black,et al.  Pharmacological classification of adenosine receptors in the sinoatrial and atrioventricular nodes of the guinea‐pig , 1998, British journal of pharmacology.

[19]  R. Barlow,et al.  The affinity and efficacy of onium salts on the frog rectus abdominis. , 1967, British journal of pharmacology and chemotherapy.

[20]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[21]  J. Giraldo,et al.  Endothelial modulation of alpha 1-adrenoceptor contractile responses in the tail artery of spontaneously hypertensive rats. , 1996, British journal of pharmacology.

[22]  P. Leff,et al.  Classification of platelet and vascular prostaglandin D2 (DP) receptors: estimation of affinities and relative efficacies for a series of novel bicylic ligands With an Appendix on Goodness‐of‐fit analyses , 1992, British journal of pharmacology.

[23]  M. Danhof,et al.  Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo , 1995, British journal of pharmacology.

[24]  M Danhof,et al.  Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[25]  E. Erdmann,et al.  Characterization of Ax Adenosine Receptors in Atrial and Ventricular Myocardium From Diseased Human Hearts , 1989, Circulation research.

[26]  G. Martin,et al.  Estimation of agonist affinity and efficacy by direct, operational model-fitting. , 1990, Journal of pharmacological methods.

[27]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[28]  J. Linden Purification and characterization of (-)[125I]hydroxyphenylisopropyladenosine, an adenosine R-site agonist radioligand and theoretical analysis of mixed stereoisomer radioligand binding. , 1984, Molecular Pharmacology.

[29]  B. Dunning,et al.  Pharmacological Strategies for Reduction of Lipid Availability , 1997, Annals of the New York Academy of Sciences.

[30]  P. Souich,et al.  Plasma Protein Binding and Pharmacological Response , 1993, Clinical pharmacokinetics.